The development of the COVID-19 vaccine was unique in that stages were permitted to proceed simultaneously. But it is important to note that no steps in this process were skipped. Learn more about how the vaccine was developed and approved below.
The COVID-19 vaccines were not rushed but were prioritized. They are a product of international collaboration, prioritization and decades of vaccine research. They have been deemed safe and effective by the U.S. Food and Drug Administration and independent scientists across the country.
Although vaccines typically take many years to produce, that isn’t because researchers are holding to determine any long-term effects. Vaccines usually take longer due to finding funds, getting authorizations, ethics permissions and determining manufacturing and distribution. It is only until Phase IV, after FDA approval and widespread distribution, that close monitoring continues.
Due to large investments from governments and philanthropic organizations across the world, the world’s top scientists and researchers were able to start working immediately and collaborating internationally.
In this case, approval for each stage of development was granted immediately or researchers were given enough resources to assist with animal ethics approval to volunteers for human trials. Typically, researchers spend months or years finding funding or searching for enough trial participants to have statistically significant data to analyze. Because the prevalence of COVID-19 is so high, it is easy for researchers to find thousands of volunteers, and it's easier to track if those volunteers get sick, therefore allowing vaccine trials to be conducted on a faster timeline.
Plus, international pharmaceutical companies increased the capacity for vaccines to be manufactured and distributed in large-scale quantities.
No steps in the FDA approval process were skipped. Rather, stages were permitted to proceed simultaneously.
The COVID-19 vaccine trials have had record-breaking numbers of human participants: Over 43,000 participants for Pfizer alone, and 15 other vaccines in Phase 3 large scale trials.
In comparison, the Ebola vaccine had approximately 15,000 participants in its Phase 3 trials.
Below is a helpful comparison from the New York Times that shows how the vaccine development was prioritized compared to a typical timeline.
And the following from the CDC shows the steps involved in developing, approving and manufacturing a new vaccine:
Regardless of any objective external pressure from the president or public, the data speaks for itself. It has been meticulously studied by the scientific community to ensure large numbers of participants, lack of adverse events and high efficacy.
Two independent committees reviewed and recommended the approval of the vaccine before reaching the FDA DSMB, VRBPAC). Additionally, the Western States Scientific Safety Review Workgroup, composed of nationally acclaimed immunization and public health scientists from California, Washington, Oregon and Nevada, have worked independently to assess the FDA’s review process.